# Vedere Bio II

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vedere-bio-ii

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.vederebio.com
- Total disclosed funding: $98M
- Latest round: Series A (May 18, 2021)
- Investors on record: 7

## About

Based in Massachusetts, US, and founded in 2019, Vedere Bio II, Inc. biotech company that is developing next-generation ocular gene therapies for vision restoration. Cyrus D. Mozayeni, M.D. is the co-founder, current CEO, and President of the company. The company is funded by Atlas Venture, Casdin Capital, Mission BioCapital, Octagon Capital, the RD Fund, and Samsara BioCapital. 

In March 2023, Vedere Bio II, Inc. discontinued its operations.

The company offers ocular gene therapies that include an optogenetics-based platform called ‘mutation-agnostic’ technology and novel AAV capsids to restore eyesight in all patients who have lost vision owing to photoreceptor cell death. The company also offers proprietary intravitreally-administered adeno-associated virus (AAV) vectors that enable office-based treatment on a global scale.

## Funding rounds

- Series A, May 18, 2021, $77M — Atlas Venture, Casdin Capital, Mission Biocapital, Samsara BioCapital, Octagon Capital Advisors, Retinal Degeneration Fund
- Series A, Jun 1, 2019, $21M — Atlas Venture, Foundation Fighting Blindness, Mission Biocapital

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Foundation Fighting Blindness — Series A
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series A
- Retinal Degeneration Fund (https://capitalatlas.ai/funds/retinal-degeneration-fund) — Series A